RE:RE:RE:Therapure Biopharma...plilong- wrote:
Rather than jump all over the poster or the competing technology that may, or may not, be worse
2) Because of Point 1, it is critical that Prometic close deals, progress their technology, and cash in on their advantages.
I always worry that Prometic (especially the CEO) "over-estimates" their value and advantage in the market, and misreads the market with respect to the ability to raise $ for development.
Plilong,
Do you really believe that the CEO and board members are living in a bubble and are not aware of what is going on, on the market????
So far, PLI proved already that they can extract on a commercial scale, proteins with a higher yield than all other fractionnator. That should gives a good idea about . I think this is kind of a proof of their advantages over other fractionnators.
The fact that plasminogen is in clinical trial, and others are coming should also validate the technology.
And I don't want to see a deal at any cost either. Maybe deals take longer than expected,but this not how I will make a validation of the technology.
You may keep hitting the same nail over and over about the managment, but so far I still believe they are the right persons to be able to deliver a solid company.
One other point, I may not be an expert in the chromatography market, but I can read between the lines.
So far, Therapure has not a single data about their capacity of extracting proteins on a commercial scale. The Upfront techonology used don't seems to be used wildly by the pasma fractionnator, and Cangene wasn't able to print cash with it neither.
So, I keep saying I have no worries about them.